Interleukin 6, serum amyloid A and haptoglobin as markers of treatment efficacy in pigs experimentally infected with Actinobacillus pleuropneumoniae.
The possibility to use acute phase proteins to monitor the elimination of a bacterial infection in pigs would facilitate an objective assessment of treatment with various antimicrobial substances. To examine this possibility, the acute phase response (IL-6, serum amyloid A (SAA), and haptoglobin) elicited by Actinobacillus pleuropneumoniae and its reduction on treatment with various antibiotics was studied in serum from specific pathogen free (SPF) pigs. Pigs were infected intranasally with A. pleuropneumoniae serotype 2, and either left as non-treated control pigs or treated with different antibiotics intramuscularly at onset of respiratory disease (20h post-infection). Pigs responded to the infection with prominent increases in activity and concentrations of IL-6, SAA, and haptoglobin. These responses were to a certain extent overlapping and covered the time span from a few hours after infection until development of detectable levels of specific antibodies (7-10 days post-infection in untreated pigs). The haptoglobin response lasted until the end of the study on day 17 and thereby partly coincided with the antibody response. Treatment with antimicrobials that effectively reduced establishment of the infection with A. pleuropneumoniae also reduced the duration of all three acute phase responses, and reduced the concentration of serum haptoglobin. In contrast, less efficacious treatments did not reduce these acute phase responses. Thus, acute phase reactants can be applied to monitor therapeutic effects of antimicrobial drugs in the pig and measurements of IL-6, SAA and haptoglobin could add valuable information about the stage of infection during a disease outbreak.
Hultén
C
C
Department of Clinical Chemistry, P.O. Box 7038, Uppsala, Sweden.
Johansson
E
E
Fossum
C
C
Wallgren
P
P
D000189:Actinobacillus Infections / Q000097:blood / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae / Q000254:growth & development*; D000210:Acute-Phase Reaction / Q000097:blood / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D001053:Apolipoproteins / Q000097:blood*; D005260:Female; D006242:Haptoglobins / Q000378:metabolism*; D015850:Interleukin-6 / Q000097:blood*; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D011001:Pleuropneumonia / Q000097:blood / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D000685:Serum Amyloid A Protein; D013047:Specific Pathogen-Free Organisms; D013552:Swine; D013553:Swine Diseases / Q000097:blood* / Q000188:drug therapy / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D001053:Apolipoproteins; D006242:Haptoglobins; D015850:Interleukin-6; D000685:Serum Amyloid A Protein